| Attending joint formulation meetings on pharmaceuticals and special medical materials. | 癌症
> 癌症：大多數類型 | 監管合作夥伴關係
> 與監管機構合作 | 100,000 | National | Sometimes | 119017792133 |
| At year-end, regulatory authorities, cancer patient advocacy groups, and clinical physicians are invited to review the NHI [全民健康保險 – National Health Insurance] reimbursement policies for that year. | 癌症
> 癌症：大多數類型 | 監管合作夥伴關係
> 與監管機構合作 | 5,000 | National | Sometimes | 119022421395 |
| Convene an annual year-end review bringing together regulatory authorities, cancer patient advocacy organisations, and clinical physicians to evaluate the NHI reimbursement policies for that calendar year. Patient advocacy groups present on unmet patient needs, clinicians conduct a cancer-type-specific assessment of the gaps between Taiwan's NHI [全民健康保險 – National Health Insurance] reimbursement coverage and oncology treatment guidelines, and dialogue is facilitated with the regulatory authorities. | 癌症
> 癌症：大多數類型 | 監管合作夥伴關係
> 參與健康技術評估（HTA）及報銷審查 | 5,000 | National | Sometimes | 119022421395 |
| We communicate patient needs to the National Health Insurance Administration in order to improve patient access to treatment. | 神經肌肉
> 脊髓性肌肉萎縮症（SMA） | 監管合作夥伴關係
> 參與健康技術評估（HTA）及報銷審查 | 100 | National | Regularly | 119053648739 |
| Convene an annual year-end review bringing together regulatory authorities, cancer patient advocacy organisations, and clinical physicians to evaluate the NHI reimbursement policies for that calendar year. Patient advocacy groups present on unmet patient needs, clinicians conduct a cancer-type-specific assessment of the gaps between Taiwan's NHI [全民健康保險 – National Health Insurance] reimbursement coverage and oncology treatment guidelines, and dialogue is facilitated with the regulatory authorities. | 癌症
> 癌症：大多數類型 | 監管合作夥伴關係
> 出席/主持與政策制定者/監管機構的會議 | 5,000 | National | Sometimes | 119022421395 |
| At year-end, regulatory authorities, cancer patient advocacy groups, and clinical physicians are invited to review the NHI [全民健康保險 – National Health Insurance/Taiwan] reimbursement policies for that year. | 癌症
> 癌症：大多數類型 | 監管合作夥伴關係
> 出席/主持與政策制定者/監管機構的會議 | 5,000 | National | Sometimes | 119022421395 |
| ... Since 2025, the government [in Taiwan] has also begun implementing its Cancer New Drug Fund policy, and our organisation is recognised as one of 13 patient advocacy groups whose efforts contributed to that successful outcome. | 癌症
> 癌症：大多數類型 | 影響政策及立法
> 影響醫療保健政策及立法 | 10,000 | National | Sometimes | 119055308347 |
| With regard to pricing, we have not had the opportunity to participate in discussions, as prices are largely determined by pharmaceutical companies' global headquarters, with patient advocacy groups afforded no meaningful role in the process. Nevertheless, we actively present patients' clinical medication needs to the government in cases where reimbursement under Taiwan's NHI [全民健康保險 – National Health Insurance] is unavailable, with the aim of securing alternative funding mechanisms to support cancer patients — such as a dedicated cancer medicines fund. | 癌症
> 癌症：大多數類型 | 影響政策及立法
> 參與公眾聆訊及諮詢 | 10,000 | National | Sometimes | 119055325391 |
| To advocate for the expansion of reimbursement coverage for new medicines to encompass broader therapeutic indications. | 一般健康
> 醫療服務提供 | 定價及可負擔性倡議
> 倡導公平藥品定價 | 5,000 | National | Sometimes | 119051396882 |
| We are advocating for the inclusion of immunotherapy for early-stage triple-negative breast cancer patients within the reimbursement coverage of the National Health Insurance scheme. | 癌症
> 癌症：乳腺癌 | 定價及可負擔性倡議
> 倡導將產品納入報銷清單／國家藥品目錄 | 10,000 | National | Regularly | 119016883314 |
| To advocate for the expansion of reimbursement coverage for new medicines to encompass broader therapeutic indications. | 一般健康
> 醫療服務提供 | 定價及可負擔性倡議
> 倡導將產品納入報銷清單／國家藥品目錄 | 5,000 | National | Sometimes | 119051396882 |
| Advocating for the expansion of reimbursement coverage for new medicines to encompass broader indications. | 癌症
> 癌症：神經內分泌腫瘤（NET） | 定價及可負擔性倡議
> 倡導將產品納入報銷清單／國家藥品目錄 | 100 | National | Sometimes | 119051407743 |
| With regard to pricing, we have not had the opportunity to participate in discussions, as prices are largely determined by pharmaceutical companies' global headquarters, with patient advocacy groups afforded no meaningful role in the process. Nevertheless, we actively present patients' clinical medication needs to the government in cases where reimbursement under Taiwan's NHI [全民健康保險 – National Health Insurance] is unavailable, with the aim of securing alternative funding mechanisms to support cancer patients — such as a dedicated cancer medicines fund. | 癌症
> 癌症：大多數類型 | 定價及可負擔性倡議
> 倡導將產品納入報銷清單／國家藥品目錄 | 10,000 | National | Sometimes | 119055325391 |
| We are advocating for the inclusion of immunotherapy for early-stage triple-negative breast cancer patients within the reimbursement coverage of the National Health Insurance scheme. | 癌症
> 癌症：乳腺癌 | 改善存取途徑
> 促進公平獲取藥物／醫療保健 | 10,000 | National | Regularly | 119016883314 |
| Advocating for the expansion of reimbursement coverage for new medicines to encompass broader indications. | 癌症
> 癌症：神經內分泌腫瘤（NET） | 改善存取途徑
> 促進公平獲取藥物／醫療保健 | 100 | National | Sometimes | 119051407743 |
| We communicate patient needs to the National Health Insurance Administration in order to improve patient access to treatment. | 神經肌肉
> 脊髓性肌肉萎縮症（SMA） | 改善存取途徑
> 促進公平獲取藥物／醫療保健 | 100 | National | Regularly | 119053648739 |
| In advocating for patient rights and access to new medicines, we engage with stakeholders, government authorities, and relevant experts to communicate patients' clinical needs and the urgency of treatment. | 癌症
> 癌症：大多數類型 | 改善存取途徑
> 促進公平獲取藥物／醫療保健 | 10,000 | National | Sometimes | 119055308347 |
| Convene an annual year-end review bringing together regulatory authorities, cancer patient advocacy organisations, and clinical physicians to evaluate the NHI reimbursement policies for that calendar year. Patient advocacy groups present on unmet patient needs, clinicians conduct a cancer-type-specific assessment of the gaps between Taiwan's NHI [全民健康保險 – National Health Insurance] reimbursement coverage and oncology treatment guidelines, and dialogue is facilitated with the regulatory authorities. | 癌症
> 癌症：大多數類型 | 以實證為基礎的患者意見
> 利用患者洞察來輔助決策 | 5,000 | National | Sometimes | 119022421395 |
| We serve as members of the Infected Persons Rights Protection Committee under Taiwan CDC [Centers for Disease Control]. | HIV
> HIV | 機構管治
> 確保在政府諮詢機構中獲得代表席位 | 5,000 | National | Regularly | 119021698989 |
| In advocating for patient rights and access to new medicines, we engage with stakeholders, government authorities, and relevant experts to communicate patients' clinical needs and the urgency of treatment. | 癌症
> 癌症：大多數類型 | 機構管治
> 在多方持份者網絡中有效運作 | 10,000 | National | Sometimes | 119055308347 |
互動
行動與倡議
5 提及
